Citations

Clear

1446 citation(s) found for "Howard, F".

Abstract TP141: Can the Human Eye Match a Computer Algorithm in Identifying Hypoperfusion in Asymptomatic Carotid Artery Stenosis?
Lazar, Ronald M. , Meyers, Philip M. , Connolly, E. Sander , Lal, Brajesh K. , Lindell, E. Paul , Siegel, Jason , Honda, T , Edwards, Lloyd J. , Brott, Thomas G. , Edwards, Lloyd J. , Marshall, Randolph S. , Meschia, James F. , Gutierrez, José , Lehman, Vance T. , Lin, Michelle , Howard, George , Huston, John , Liebeskind, David S.

Mayo Clinic

Stroke | June 21, 2021 | Volume: 51 | Issue: Suppl_1 | Pages: No page available

10.1161/str.51.suppl_1.tp141 Get It

Background: Perfusion weighted imaging on MRI (MRP) and computerized tomography perfusion (CTP) are increasingly required to manage large vessel disease. Computerized algorithms can quantify perfusion data, but the programs are expensive and not widely used outside acute stroke evaluation. We aimed to determine how well human observers can identify asymmetries in cerebral perfusion images compared with an automated computer algorithm. Methods: Ten clinicians experienced in treating carotid artery disease (4 vascular neurologists, 3 neuroradiologists, 1 vascular surgeon, 1 neurosurgeon, 1 interventional radiologist) were given 28 post-processed, color-coded, axial-slice MRP scans from patients in the Carotid Revascularization Endovascular versus Stenting Trial - Hemodynamics (CREST-H) study. All patients had >70%, unilateral, asymptomatic carotid artery stenosis and had varying degrees of time-to-peak (TTP) delay on the side of stenosis, ranging from 0 to 2 secs, quantified by a semi-automated system that computes quantitative perfusion maps, using deconvolution of tissue and arterial signals (Olea, Cambridge, MA). A minimum volume of 10cc was required for a given TTP delay. Clinicians were asked to determine asymmetry (y/n) and side of occlusion for each case. Number of correct responses that matched the computer output were tallied. Results: We averaged correct responses by the 10 clinicians for cases at each increment of TTP delay; (Figure). At TTP delays ≥1.5 seconds, accuracy was ≥80%. At 1.25 sec accuracy fell to 60%, and at ≤ 1 sec, accuracy was ≤50%. For TTP=0 (no asymmetry), accuracy was 71%. Conclusions: Visual impression of hemodynamic asymmetry among experienced clinicians was reasonably accurate for TTP delays ≥1.5 seconds, but declined with more subtle asymmetries. Depending on the clinical impact of TTP delays (for CREST-H: correlation with cognitive decline), experienced clinicians may perform as well as an automated algorithm.
Abstract TP131: Carotid Stenosis and Polyvascular Disease
Lal, Brajesh K. , Roubin, Gary S., Teal, Philip , Brown, Robert D. , Barrett, Kevin M. , Chimowitz, Marc I. , Lazar, Ronald M. , Moore, Wesley S. , Moy, Claudia S., Voeks, Jenifer H. , Brott, Thomas G. , Chaturvedi, Seemant , Meschia, James F. , Howard, George , Turan, Tanya N. , Demaerschalk, Bart M. , Howard, Virginia J. , Huston, John

Mayo Clinic

Stroke | June 21, 2021 | Volume: 51 | Issue: Suppl_1 | Pages: No page available

10.1161/str.51.suppl_1.tp131 Get It

Background: Presence of atherosclerotic disease in more than one vascular bed (polyvascular disease) is associated with an increased risk of long-term vascular events. In the setting of asymptomatic carotid stenosis, the predictors of disease in other vascular beds is not well delineated. Objective: To identify the frequency and predictors of disease in other vascular beds the CREST 2 randomized trial population with hemodynamically significant stenosis. Methods: Recorded baseline characteristics among CREST 2 participants included: demographics, past medical history, lifestyle factors, and laboratory studies. Each variable was tested against three potential definitions of disease in other beds (cardiac, peripheral arterial disease (PAD) or disease in cardiac + PAD). Statistical analysis was done with Chi square and t tests as appropriate. Results: Data from 1447 patients were available for analysis. In these subjects with carotid disease, 51% also had cardiac disease, 24% also had PAD, and 16% had disease in in both cardiac and PAD. There was no relationship between age or race and presence of disease in other beds. Those with cardiac disease were more likely to be male. Diabetes, hypertension, hypercholesterolemia, and former history of smoking were all more common in those with either cardiac and PAD (TABLE). Elevated triglyceride and low HDL levels were also associated with all three definitions of disease in other beds. Those with either PAD or cardiac + PAD were more likely to be current smokers. Conclusions: Among CREST 2 participants, several medical conditions and lifestyle factors were associated with an increased frequency of disease in other vascular beds. Smoking, in particular, appears to be more common in those with PAD. Future analyses will address whether those with disease in other beds have higher rates of stroke or death.
Abstract TP123: Baseline Differences in Risk Factor Control Between CREST-2 and SAMMPRIS
Voeks, Jenifer H. , Barrett, Kevin M. , Brown, Robert D. , Chimowitz, Marc I. , Emmady, Prabhu D. , Jones, Michael R. , Lal, Brajesh K. , Lazar, Ronald M. , Moore, Wesley S. , Moy, Claudia S., Roldan, Ana , Roubin, Gary S., Sangha, Navdeep , Brott, Thomas G. , Turan, Tanya N. , Chaturvedi, Seemant , Demaerschalk, Bart M. , Howard, George , Howard, Virginia J. , Huston, John , Meschia, James F.

Mayo Clinic

Stroke | June 21, 2021 | Volume: 51 | Issue: Suppl_1 | Pages: No page available

10.1161/str.51.suppl_1.tp123 Get It

Baseline Differences in Risk Factor Control and Medication Use Between 2 Trials Employing Intensive Medical Management (SAMMPRIS & CREST2) Background: The CREST2 trial Intensive Medical Management (IMM) protocol was adapted from the SAMMPRIS trial. However, since the 2011 publication of initial results of SAMMPRIS, there has been a greater appreciation for the importance of risk factor control in patients at risk of stroke associated with atherosclerosis. Therefore, we sought to determine differences in baseline risk factor control and medication use between SAMMPRIS and CREST2. Methods: Baseline risk factor and medication use data from 451 patients enrolled in SAMMPRIS (2008-2011) with severe symptomatic intracranial atherosclerosis and 1473 patients enrolled in CREST2 (2014-2019) with severe asymptomatic carotid stenosis were compared using the Chi-square test and t-test. Results: The Table shows baseline risk factor values and medications. SAMMPRIS patients were younger but had significantly worse risk factor control than CREST2 patients for all measures. There was no significant difference in statin use at baseline, but the mean SAMMPRIS subjects’ LDL was 16.1 mg/dL higher than in CREST2. CREST2 patients had higher rates of use of angiotensin receptor blockers (ARB), calcium channel blockers (CCB), and thiazides, but lower rates of use of angiotensin converting enzyme (ACE) inhibitors. Conclusions: Despite being older, CREST2 patients have significantly better baseline risk factor profiles than SAMMPRIS patients. This could be due to greater appreciation of the importance of risk factor control and healthy lifestyle habits for stroke prevention or more aggressive treatment targets in guideline recommendations. Although risk factor control appears to be improving since SAMMPRIS, many CREST2 patients are still not meeting recommended risk factor goals at baseline and may benefit from IMM protocols.
Abstract 70: Age and Outcomes After Carotid Stenting and Endarterectomy: A Pooled Analysis of the Crest and Act I Trials
Voeks, Jenifer H. , Matsumura, Jon S. , Rosenfield, Ken, Roubin, Gary S., Brott, Thomas G. , Hanlon, Bret M. , Howard, George

Mayo Clinic

Stroke | June 21, 2021 | Volume: 51 | Issue: Suppl_1 | Pages: No page available

10.1161/str.51.suppl_1.70 Get It

Introduction: Using pooled data from randomized trials of symptomatic patients assigned to carotid artery stenting (CAS) versus carotid endarterectomy (CEA), we have previously shown age to be an effect modifier, with increasing risk at older ages for CAS but not for CEA. To extend assessment of age as an effect modifier to the asymptomatic population, we combined the asymptomatic patients from CREST with the patients from ACT I. Methods: We analyzed data from 2544 subjects with >= 70% carotid stenosis randomized to CAS or CEA in addition to standard management of cardiovascular risk factors. CREST enrolled 1091 (548 CAS, 543 CEA) and ACT I enrolled 1453 (1089 CAS, 364 CEA) asymptomatic patients less than 80 years old (upper age eligibility in ACT I). We examined the impact of age on risk within CAS-treated and CEA-treated patients using Kaplan-Meier methods. Age was considered in three strata (< 65, 65 to 74, and 75+). The pre-specified, primary composite endpoint was stroke, myocardial infarction, or death during the periprocedural period or any ipsilateral stroke within 4 years after randomization. Results: For patients assigned to CAS, risk differed between the age strata (p <0.0001) where relative to those under age 65, there was no difference in risk for those aged 65 to 74 (HR = 1.3 ; 95% CI: 0.7, 2.3, p=0.38), but those aged 75+ were at substantially higher risk (HR = 2.9; 95% CI: 1.5, 5.5, p=0.001). In contrast, risk did not differ by age strata (p = 0.80) for those assigned to CEA. Conclusions: Age-related risk factors, e.g. carotid anatomy and underlying cerebral pathology, should be considered before selecting patients aged 75+ for CAS.
Abstract TP132: Selection and Activation of Sites in a Large Multi-Center Randomized Clinical Trial
Brown, Robert D. , Tom, MeeLee , Longbottom, Mary, Voeks, Jenifer H. , Kadiric, Eldina, Lal, Brajesh K. , Brott, Thomas G. , Demaerschalk, Bart M. , Howard, Virginia J. , Meschia, James F.

Mayo Clinic

Stroke | June 21, 2021 | Volume: 48 | Issue: suppl_1 | Pages: No page available

10.1161/str.48.suppl_1.tp132 Get It

Introduction: Careful selection and timely activation of clinical sites in multicenter clinical trials is critical for successful enrollment, subject safety, and generalizability of results. Methods: In the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2), a multidisciplinary Site Selection Committee evaluated applicants referred via participation in CREST, CREST principal investigators (PIs) and other investigators, StrokeNet and industry partners. Data for consideration included performance metrics in CREST and other carotid trials and a site selection questionnaire containing information on the investigators as well as quantitative data on carotid procedures performed. Any FDA warning letters were reviewed. Results: The Committee met bi-weekly for 36 months (n=64 meetings). Applications from 176 sites between March 2014 and July 2016 were evaluated: 153 were approved, 7 are under Committee review, 5 were approved but withdrew, 5 were placed on a waiting list, and 6 were rejected. One-hundred-four sites have completed the regulatory and training requirements to randomize: 51 (49%) academic medical centers, 31 (30%) private hospital-based centers, 16 (15%) private office-based practices, and 6 (6%) Veterans Administration medical centers. The mean times from application-to- approval was 5.2 weeks (interquartile range, 1.9, 6.2), and from approval-to-randomization status was 46.7 weeks (interquartile range, 35.4, 51.7). Specialties of the 104 site PIs are vascular surgery for 35 (33.7%), cardiology for 30 (28.8%), neurology for 25 (24%), neurosurgery for 8 (7.7%), interventional radiology for 4 (3.8%), and interventional neuroradiology for 2 (1.9%). Conclusions: Careful site selection is time-consuming for prospective sites and for trial leadership. Times from application-to-site-approval were modest (mean = 5.2 weeks), in contrast to the times for completing regulatory and training requirements (mean = 46.7 weeks). However, subject enrollment by teams from a wide range of medical centers led by a multi-disciplinary cohort of PIs will promote the generalizability of trial results.
Abstract TMP34: The Challenge and Yield of Racially and Ethnically Diverse Patient Populations in Low Event-Rate Clinical Trials
Sheffet, Alice J., Sam, Albert D., Jamil, Zafar, Weaver, Fred A., Chiu, David, Voeks, Jenifer H. , Tom, MeeLee , Hughes, Susan , Flaxman, Linda, Longbottom, Mary, Brott, Thomas G. , Howard, Virginia J.

Mayo Clinic

Stroke | June 21, 2021 | Volume: 48 | Issue: suppl_1 | Pages: No page available

10.1161/str.48.suppl_1.tmp34 Get It

Background: Concern for underrepresentation of minorities in clinical trials has focused on enrollment proportions and generalizability. The interplay of trial event-rates with diversity has not been emphasized. Methods: The Carotid Revascularization Endarterectomy vs Stent Trial (CREST) randomized 2502 patients and compared them by race, ethnicity, baseline characteristics, and primary outcome (any peri-procedural stroke, death or MI and subsequent ipsilateral stroke up to 10 years); those with unknown race or ethnicity were excluded. Proportional hazards models adjusting for age, sex, symptomatic status and treatment were used to test for a treatment by race/ethnicity interaction. Results: One-hundred-nine patients (4.4%) were black, 32 (1.3%) Asian, 2332 (93.4%) white, 11 (0.4%) other by self-report, and 18 (0.7%) unknown; 90 (3.6%) were Hispanic, 2377 (95%) non-Hispanic, and 35 (1.4%) unknown. Compared to whites, racial minorities were younger (mean age 67±8.9 vs 69±8.8, p=0.004), more often female (44% vs 34%, p=0.01), symptomatic (63 vs 52%, p=0.01), and diabetic (51% vs 29%, p<0.0001), but less often dyslipidemic (76% vs 85%, p=0.004), current smokers (19% vs 27%, p=0.04), or had a history of cardiovascular disease (34% vs 46%, p=0.007). Hispanics were more often diabetic (48% vs 30%, p=0.0002). The rate of the primary endpoint was 10.9%±0.9% at 10 years, and did not differ by race or ethnicity (p inter >0.24). In the context of this low rate, even if minority recruitment were increased to represent 50% of study participants, and if the treatment difference in one race were a greater hazard of HR = 1.49 (anticipated alternative hypothesis), then the hazard ratio in the other group would need to be <0.73, or >3.31, to have 90% power of detection. Conclusions: The proportion of racial and ethnicity participation in CREST was suboptimal at < 10%. Primary outcomes did not differ by minority or ethnic status. However, in low event-rate trials very high and even unrealistic enrollment goals for diversity, for example ≥50%, may still be insufficient for detection of outcome differences by race or ethnicity.
Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance)
Patel, Jai N., Jiang, Chen, Owzar, Kouros, Mulkey, Flora, Luzum, Jasmine A., Mamon, Harvey J., Haller, Daniel G., Dragovich, Tomislav, Alberts, Steven R., Bjarnason, Georg, Willet, Christopher G., Niedzwiecki, Donna, Enzinger, Peter, Ratain, Mark J., Fuchs, Charles, McLeod, Howard L., Niedzwiecki, Donna , Owzar, Kouros , Luzum, Jasmine A. , Niedzwiecki, Donna , Luzum, Jasmine A , Patel, Jai N., Jiang, Chen, Mulkey, Flora, Mamon, Harvey J., Haller, Daniel G., Dragovich, Tomislav, Alberts, Steven R., Bjarnason, Georg, Willet, Christopher G., Enzinger, Peter, Ratain, Mark J., Fuchs, Charles, McLeod, Howard L.

Mayo Clinic

Pharmacogenetics and Genomics | June 20, 2021 | Volume: 31 | Issue: 9 | Pages: 215-220

10.1097/fpc.0000000000000442 | PMID 34149004 Get It

There is a lack of pharmacogenetic predictors of outcome in gastric cancer patients. The aim of this study was to assess previously identified candidate genes associated with 5-fluorouracil (5-FU), cisplatin, or epirubicin toxicity or response in a cohort of resected gastric cancer patients treated on CALGB (Alliance) 80101. Gastric or gastroesophageal cancer patients randomized to adjuvant 5-FU/leucovorin or epirubicin/cisplatin/5-FU before and after 5-FU chemoradiation were genotyped for single nucleotide polymorphisms (SNPs) in GSTP1 (rs1695), ERCC1 (rs11615 and rs3212986), XRCC1 (rs25487), UGT2B7 (rs7439366) and the 28 base-pair tandem repeats in TYMS (rs34743033). Logistic regression and log rank tests were used to assess the association between each SNP and incidence of grade 3/4 neutropenia and leukopenia, overall (OS) and progression-free survival (PFS), respectively. Toxicity endpoint analyses were adjusted for the treatment arm, while OS and PFS were also adjusted for performance status, sex, age, lymph node involvement, and primary tumor site and size. Of 281 subjects with successful genotyping results and available clinical (toxicity and efficacy) data, 166 self-reported non-Hispanic White patients were included in the final analysis. There was a lack of evidence of an association among any SNPs tested with grade 3/4 neutropenia and leukopenia or OS and PFS. Age, lymph node involvement, and primary tumor size were significantly associated with OS and PFS. This study failed to confirm results of previous gastric cancer pharmacogenetic studies.
Neuroendovascular Management of Acute Ischemic Basilar Strokes: 2-Dimensional Operative Video
Porto, Guilherme , Sattur, Mithun G. , Kasab, Sami Al , Spiotta, Alejandro M , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Levitt, Michael , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Rodríguez, Rafael, Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Turner, Raymond D , Veznedaroglu, Erol, Welch, Babu G. , Porto, Guilherme B F , Schirmer, Clemens M , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael, Levy, Elad I. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Siddiqui, Adnan H. , Tawk, Rabih G. , Thomas, Ajith J , White, Jonathan Samuel

Mayo Clinic

Operative Neurosurgery | June 15, 2021 | Volume: 21 | Issue: 4 | Pages: E346-E347

10.1093/ons/opab180 | PMID 34131725 Get It

Abstract Basilar artery occlusions (BAOs) are devastating ischemic strokes that account for 1% of all strokes with high morbidity and mortality; however, neuroendovascular techniques such as ADAPT have recently revolutionized the clinical outcomes of these patients. 1-3 Common underlying pathology in patients with BAO include intracranial atherosclerotic disease (ICAD) as well as thromboembolic origin. 4 Basilar artery ICAD in a setting of acute stroke portends a poor prognosis and post-thrombectomy residual critical flow limiting stenosis treatment options, including balloon angioplasty with or without stent placement. 5-7 We present a video illustration of neuroendovascular technique and challenges encountered when managing this pathology. Image at 5:42 reprinted with permission from Alawieh et al, Lessons learned over more than 500 stroke thrombectomies using ADAPT with increasing aspiration catheter size, Neurosurgery , 86(1), 2020, pp. 61-70, with permission from the Congress of Neurological Surgeons. 1
Early role for a Na + ,K + -ATPase ( ATP1A3 ) in brain development
Smith, Richard S. , Akula, Shyam K. , Neil, Jennifer E., Wang, Yidi , Hill, Robert , Goldman, Melissa , Mullally, Christopher D. , Reed, Nora , Bello‐Espinosa, Luis , Flores‐Sarnat, Laura , Monteiro, Fabíola Paoli , Casella, Erasmo Barbante , Barkovich, A. James , Gonzalez–Heydrich, Joseph , Florio, Marta , Akula, Shyam K , Wang, Yidi , Bello-Espinosa, Luis , Erasmo, Casella B , Vairo, Filippo , Barkovich, A James , Gonzalez-Heydrich, Joseph , Walsh, Christopher A , Hill, R. Sean, Vairo, Filippo Pinto e , Morava, Éva , Brownstein, Catherine A. , McCarroll, Steven A. , Walsh, Christopher A.

Mayo Clinic

Proceedings of the National Academy of Sciences | June 14, 2021 | Volume: 118 | Issue: 25 | Pages: No page available

10.1073/pnas.2023333118 | PMID 34161264 Get It

Significance By evaluating children with a malformed cerebral cortex, we identified an ATPase pump (ATP1A3) with an early role in brain development. The ATP1A3 pump maintains the physiological concentration of sodium and potassium ions in cells, a process critical for osmotic equilibrium and membrane potential across several developing cell populations. We employed single-cell sequencing approaches to identify key enrichments for ATP1A3 expression during human cortex development. Unravelling this early cell-type–specific pathophysiology in the developing brain offers a potential basis for the treatment of ATP1A3 -related diseases affecting prenatal and early childhood development.
Super-Refractory Status Epilepticus in Children: A Retrospective Cohort Study
Vasquez, Alejandra , Farias‐Moeller, Raquel , Sánchez-Fernández, Iván, Amengual‐Gual, Marta , Anderson, Anne E. , Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Gaillard, William D. , Goldstein, Joshua , Goodkin, Howard P. , McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Piantino, Juan , Riviello, James J. , Sands, Tristan T. , Sannagowdara, Kumar , Tasker, Robert C. , Topjian, Alexis , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Gaillard, William D , Mikati, Mohamad A , Morgan, Lindsey A , Abend, Nicholas S. , Arya, Ravindra , Glauser, Tracy A. , Guerriero, Rejean M , Lai, Yi‐Chen , Novotny, Edward J. , Tchapyjnikov, Dmitry , Loddenkemper, Tobias

Mayo Clinic

Pediatric Critical Care Medicine | June 14, 2021 | Volume: 22 | Issue: 12 | Pages: e613-e625

10.1097/pcc.0000000000002786 | PMID 34120133 Get It

OBJECTIVES: To characterize the pediatric super-refractory status epilepticus population by describing treatment variability in super-refractory status epilepticus patients and comparing relevant clinical characteristics, including outcomes, between super-refractory status epilepticus, and nonsuper-refractory status epilepticus patients. DESIGN: Retrospective cohort study with prospectively collected data between June 2011 and January 2019. SETTING: Seventeen academic hospitals in the United States. PATIENTS: We included patients 1 month to 21 years old presenting with convulsive refractory status epilepticus. We defined super-refractory status epilepticus as continuous or intermittent seizures lasting greater than or equal to 24 hours following initiation of continuous infusion and divided the cohort into super-refractory status epilepticus and nonsuper-refractory status epilepticus groups. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We identified 281 patients (157 males) with a median age of 4.1 years (1.3–9.5 yr), including 31 super-refractory status epilepticus patients. Compared with nonsuper-refractory status epilepticus group, super-refractory status epilepticus patients had delayed initiation of first nonbenzodiazepine-antiseizure medication (149 min [55–491.5 min] vs 62 min [33.3–120.8 min]; p = 0.030) and of continuous infusion (495 min [177.5–1,255 min] vs 150 min [90–318.5 min]; p = 0.003); prolonged seizure duration (120 hr [58–368 hr] vs 3 hr [1.4–5.9 hr]; p < 0.001) and length of ICU stay (17 d [9.5–40 d] vs [1.8–8.8 d]; p < 0.001); more medical complications (18/31 [58.1%] vs 55/250 [22.2%] patients; p < 0.001); lower return to baseline function (7/31 [22.6%] vs 182/250 [73.4%] patients; p < 0.001); and higher mortality (4/31 [12.9%] vs 5/250 [2%]; p = 0.010). Within the super-refractory status epilepticus group, status epilepticus resolution was attained with a single continuous infusion in 15 of 31 patients (48.4%), two in 10 of 31 (32.3%), and three or more in six of 31 (19.4%). Most super-refractory status epilepticus patients (30/31, 96.8%) received midazolam as first choice. About 17 of 31 patients (54.8%) received additional treatments. CONCLUSIONS: Super-refractory status epilepticus patients had delayed initiation of nonbenzodiazepine antiseizure medication treatment, higher number of medical complications and mortality, and lower return to neurologic baseline than nonsuper-refractory status epilepticus patients, although these associations were not adjusted for potential confounders. Treatment approaches following the first continuous infusion were heterogeneous, reflecting limited information to guide clinical decision-making in super-refractory status epilepticus.